{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:14:31Z","timestamp":1781550871302,"version":"3.54.5"},"reference-count":143,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T00:00:00Z","timestamp":1615939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Sarcopenia is characterized by a skeletal muscle disorder with progressive and generalized loss of muscle mass and function, and it increases the risk of adverse outcomes with considerable prevalence in patients with chronic liver disease. Sarcopenia in chronic liver disease underlies complicated and multifactorial mechanisms for pathogenesis, including alterations in protein turnover, hyperammonemia, energy disposal, hormonal changes, and chronic inflammation. The key contribution to sarcopenia in patients with chronic liver diseases can be the hyperammonemia-induced upregulation of myostatin, which causes muscle atrophy via the expression of atrophy-related genes. Several clinical studies on emerging treatment options for sarcopenia have been reported, but only a few have focused on patients with chronic liver diseases, with mostly nutritional and behavioral interventions being carried out. The inhibition of the myostatin-activin receptor signaling pathway and hormonal therapy might be the most promising therapeutic options in combination with an ammonia-lowering approach in sarcopenic patients with chronic liver diseases. This review focuses on current and emerging treatment options for sarcopenia in chronic liver diseases with underlying mechanisms to counteract this condition.<\/jats:p>","DOI":"10.3390\/life11030250","type":"journal-article","created":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T21:43:31Z","timestamp":1616017411000},"page":"250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emerging Treatment Options for Sarcopenia in Chronic Liver Disease"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-7351","authenticated-orcid":false,"given":"Yun","family":"Kim","sequence":"first","affiliation":[{"name":"Hanyang Medicine-Engineering-Bio Collaborative &amp; Comprehensive Center for Drug Development, Hanyang University, Seoul 04763, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ageing\/afz046","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"990S","DOI":"10.1093\/jn\/127.5.990S","article-title":"Sarcopenia: Origins and clinical relevance","volume":"127","author":"Rosenberg","year":"1997","journal-title":"J. Nutr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jamda.2011.04.014","article-title":"Sarcopenia with limited mobility: An international consensus","volume":"12","author":"Morley","year":"2011","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jamda.2013.11.025","article-title":"Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia","volume":"15","author":"Chen","year":"2014","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3945\/ajcn.2009.28047","article-title":"Longitudinal study of muscle strength, quality, and adipose tissue infiltration","volume":"90","author":"Delmonico","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"Baeyens","year":"2010","journal-title":"Age Ageing"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40200-017-0302-x","article-title":"Prevalence of sarcopenia in the world: A systematic review and meta- analysis of general population studies","volume":"16","author":"Shafiee","year":"2017","journal-title":"J. Diabetes Metab. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.02.051","article-title":"Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008\u20132011)","volume":"63","author":"Lee","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/hep.26716","article-title":"Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study","volume":"59","author":"Hong","year":"2014","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7570\/jomes.2019.28.2.129","article-title":"Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease","volume":"28","author":"Chung","year":"2019","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.28376","article-title":"Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008\u20132011)","volume":"63","author":"Lee","year":"2016","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","article-title":"Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis","volume":"66","author":"Koo","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5009\/gnl18070","article-title":"Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study","volume":"13","author":"Lee","year":"2019","journal-title":"Gut Liver"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kim, G., Kang, S.H., Kim, M.Y., and Baik, S.K. (2017). Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186990"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jhep.2016.07.040","article-title":"Sarcopenia from mechanism to diagnosis and treatment in liver disease","volume":"65","author":"Dasarathy","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cgh.2011.08.028","article-title":"Muscle wasting is associated with mortality in patients with cirrhosis","volume":"10","author":"Prado","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Tateyama, M., Naoe, H., Tanaka, M., Tanaka, K., Narahara, S., Tokunaga, T., Kawasaki, T., Yoshimaru, Y., Nagaoka, K., and Watanabe, T. (2020). Loss of skeletal muscle mass affects the incidence of minimal hepatic encephalopathy: A case control study. BMC Gastroenterol., 20.","DOI":"10.1186\/s12876-020-01501-x"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/lt.25591","article-title":"Sarcopenia in Chronic Liver Disease: Impact on Outcomes","volume":"25","author":"Ooi","year":"2019","journal-title":"Liver Transpl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/ajt.13732","article-title":"Systematic Review and Meta-Analysis of the Impact of Computed Tomography-Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation","volume":"16","author":"Levolger","year":"2016","journal-title":"Am. J. Transpl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3748\/wjg.v23.i5.899","article-title":"Frailty is independently associated with increased hospitalisation days in patients on the liver transplant waitlist","volume":"23","author":"Sinclair","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/tri.13048","article-title":"Low skeletal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation-a retrospective study","volume":"31","author":"Buettner","year":"2018","journal-title":"Transpl. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1097\/MEG.0000000000001415","article-title":"Relationship between pre-sarcopenia and quality of life in patients with chronic liver disease: A cross-sectional study","volume":"31","author":"Ohashi","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1042\/bj1500235","article-title":"Skeletal-muscle growth and protein turnover","volume":"150","author":"Millward","year":"1975","journal-title":"Biochem. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1152\/japplphysiol.91375.2008","article-title":"Regulatory mechanisms of skeletal muscle protein turnover during exercise","volume":"106","author":"Rose","year":"2009","journal-title":"J. Appl. Physiol. (1985)"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10408363.2011.586171","article-title":"Proteolysis in illness-associated skeletal muscle atrophy: From pathways to networks","volume":"48","author":"Wing","year":"2011","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10409238.2013.857291","article-title":"Signaling pathways controlling skeletal muscle mass","volume":"49","author":"Egerman","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.2001.20764","article-title":"Molecular mechanisms regulating protein turnover in muscle","volume":"37","author":"Price","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrm3522","article-title":"Amino acid signalling upstream of mTOR","volume":"14","author":"Jewell","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.numecd.2012.02.002","article-title":"Role of satellite cells in muscle growth and maintenance of muscle mass","volume":"23","author":"Pallafacchina","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1152\/physrev.00043.2011","article-title":"Satellite cells and the muscle stem cell niche","volume":"93","author":"Yin","year":"2013","journal-title":"Physiol. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2044-5040-1-4","article-title":"Regulation of skeletal muscle growth by the IGF1-Akt\/PKB pathway: Insights from genetic models","volume":"1","author":"Schiaffino","year":"2011","journal-title":"Skelet. Muscle"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1083\/jcb.200207056","article-title":"Myostatin negatively regulates satellite cell activation and self-renewal","volume":"162","author":"McCroskery","year":"2003","journal-title":"J. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1007\/s00018-014-1689-x","article-title":"Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways","volume":"71","author":"Rodriguez","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1042\/cs0780613","article-title":"Skeletal muscle and whole-body protein turnover in cirrhosis","volume":"78","author":"Morrison","year":"1990","journal-title":"Clin. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1152\/ajpendo.00333.2001","article-title":"Impairment of albumin and whole body postprandial protein synthesis in compensated liver cirrhosis","volume":"282","author":"Tessari","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"G598","DOI":"10.1152\/ajpgi.00355.2007","article-title":"Phenylalanine and tyrosine kinetics in compensated liver cirrhosis: Effects of meal ingestion","volume":"295","author":"Tessari","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MCO.0b013e32833383af","article-title":"Effect of liver cirrhosis on phenylalanine and tyrosine metabolism","volume":"13","author":"Tessari","year":"2010","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0016-5085(92)90849-T","article-title":"In vivo differences between the turnover rates of leucine and leucine\u2019s ketoacid in stable cirrhosis","volume":"103","author":"McCullough","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11011-008-9122-5","article-title":"Interorgan ammonia trafficking in liver disease","volume":"24","author":"Jalan","year":"2009","journal-title":"Metab. Brain Dis."},{"key":"ref_40","first-page":"G1145","article-title":"Effect of liver disease and transplantation on urea synthesis in humans: Relationship to acid-base status","volume":"276","author":"Shangraw","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"18162","DOI":"10.1073\/pnas.1317049110","article-title":"Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism","volume":"110","author":"Qiu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"E983","DOI":"10.1152\/ajpendo.00183.2012","article-title":"Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis","volume":"303","author":"Qiu","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/jcsm.12262","article-title":"Myostatin and beyond in cirrhosis: All roads lead to sarcopenia","volume":"8","author":"Dasarathy","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.21037\/tgh.2018.07.06","article-title":"Branched-chain amino acids in liver diseases","volume":"3","author":"Tajiri","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1113\/JP272796","article-title":"Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress","volume":"594","author":"Davuluri","year":"2016","journal-title":"J. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s005350200082","article-title":"Severe catabolic state after prolonged fasting in cirrhotic patients: Effect of oral branched-chain amino-acid-enriched nutrient mixture","volume":"37","author":"Nakaya","year":"2002","journal-title":"J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S0016-5085(98)70033-2","article-title":"Quantification of gluconeogenesis in cirrhosis: Response to glucagon","volume":"115","author":"Bugianesi","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI111142","article-title":"Nature and quantity of fuels consumed in patients with alcoholic cirrhosis","volume":"72","author":"Owen","year":"1983","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jceh.2017.11.001","article-title":"Nutrition and Muscle in Cirrhosis","volume":"7","author":"Anand","year":"2017","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1101\/gad.269324.115","article-title":"GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2","volume":"29","author":"Ye","year":"2015","journal-title":"Genes Dev."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Anda, S., Zach, R., and Grallert, B. (2017). Activation of Gcn2 in response to different stresses. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0182143"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.15252\/embr.201642195","article-title":"The integrated stress response","volume":"17","author":"Koryga","year":"2016","journal-title":"EMBO Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1083\/jcb.200408003","article-title":"Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response","volume":"167","author":"Lu","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MCO.0000000000000426","article-title":"Hyperammonemia and proteostasis in cirrhosis","volume":"21","author":"Dasarathy","year":"2018","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/hep.27717","article-title":"Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis","volume":"61","author":"Tsien","year":"2015","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jhep.2016.06.004","article-title":"Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis","volume":"65","author":"Davuluri","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00535-019-01605-6","article-title":"Sarcopenia in cirrhosis: From pathogenesis to interventions","volume":"54","author":"Ebadi","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2012.04347.x","article-title":"Low testosterone levels as an independent predictor of mortality in men with chronic liver disease","volume":"77","author":"Grossmann","year":"2012","journal-title":"Clin. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s001980170094","article-title":"Bone disease after liver transplantation: A long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics","volume":"12","author":"Monegal","year":"2001","journal-title":"Osteoporos. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"615","DOI":"10.5604\/01.3001.0012.0930","article-title":"Association between Low Testosterone Levels and Sarcopenia in Cirrhosis: A Cross-sectional Study","volume":"17","author":"Low","year":"2018","journal-title":"Ann. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jhep.2016.06.007","article-title":"Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial","volume":"65","author":"Sinclair","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1210\/en.2009-1177","article-title":"Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways","volume":"151","author":"Kovacheva","year":"2010","journal-title":"Endocrinology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2006.03.005","article-title":"\u2018Endocrine NAFLD\u2019 a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis","volume":"44","author":"Lonardo","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.mce.2017.06.010","article-title":"Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects","volume":"464","author":"Anderson","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ncb1101-1014","article-title":"Akt\/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo","volume":"3","author":"Bodine","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/ncb1101-1009","article-title":"Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K\/Akt\/mTOR and PI(3)K\/Akt\/GSK3 pathways","volume":"3","author":"Rommel","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00223-012-9645-y","article-title":"Vitamin D and its role in skeletal muscle","volume":"92","author":"Ceglia","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jcsm.12030","article-title":"Endocrine determinants of incident sarcopenia in middle-aged and elderly European men","volume":"6","author":"Gielen","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/liv.13682","article-title":"Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening","volume":"38","author":"Marcellin","year":"2018","journal-title":"Liver Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"597583","DOI":"10.3389\/fendo.2020.597583","article-title":"Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides","volume":"11","author":"Korinkova","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1155\/2014\/757929","article-title":"Biomarkers in nonalcoholic fatty liver disease","volume":"28","author":"Neuman","year":"2014","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8162421","DOI":"10.1155\/2017\/8162421","article-title":"The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications","volume":"2017","author":"Alisi","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1079\/BJN20041213","article-title":"Adipokines: Inflammation and the pleiotropic role of white adipose tissue","volume":"92","author":"Trayhurn","year":"2004","journal-title":"Br. J. Nutr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"E336","DOI":"10.1152\/ajpendo.00366.2001","article-title":"TNF-alpha impairs heart and skeletal muscle protein synthesis by altering translation initiation","volume":"282","author":"Lang","year":"2002","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/rr67","article-title":"Tumor necrosis factor-alpha and muscle wasting: A cellular perspective","volume":"2","author":"Reid","year":"2001","journal-title":"Respir. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.tem.2016.03.002","article-title":"Cytokine Signaling in Skeletal Muscle Wasting","volume":"27","author":"Zhou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1096\/fj.04-2364com","article-title":"TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1\/MAFbx in skeletal muscle","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2044-5040-2-2","article-title":"TNF-alpha- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism","volume":"2","author":"Zufferli","year":"2012","journal-title":"Skelet. Muscle"},{"key":"ref_82","first-page":"871","article-title":"Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha","volume":"12","author":"Li","year":"1998","journal-title":"FASEB J."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Bhatnagar, S., Panguluri, S.K., Gupta, S.K., Dahiya, S., Lundy, R.F., and Kumar, A. (2010). Tumor necrosis factor-alpha regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013262"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1789395","DOI":"10.1155\/2017\/1789395","article-title":"Muscle Lipid Metabolism: Role of Lipid Droplets and Perilipins","volume":"2017","author":"Morales","year":"2017","journal-title":"J. Diabetes Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2007.01.002","article-title":"Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance","volume":"5","author":"Holland","year":"2007","journal-title":"Cell Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2337\/diabetes.51.7.2005","article-title":"Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha","volume":"51","author":"Itani","year":"2002","journal-title":"Diabetes"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/0363546506297539","article-title":"Fatty infiltration and atrophy of the rotator cuff do not improve after rotator cuff repair and correlate with poor functional outcome","volume":"35","author":"Gladstone","year":"2007","journal-title":"Am. J. Sports Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jse.2007.02.122","article-title":"Correlation of atrophy and fatty infiltration on strength and integrity of rotator cuff repairs: A study in thirteen patients","volume":"16","author":"Gerber","year":"2007","journal-title":"J. Shoulder Elbow Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.arr.2016.09.008","article-title":"Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis","volume":"35","author":"Kalinkovich","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Kohara, K., Ochi, M., Tabara, Y., Nagai, T., Igase, M., and Miki, T. (2011). Leptin in sarcopenic visceral obesity: Possible link between adipocytes and myocytes. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024633"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2337\/diabetes.51.12.3391","article-title":"Interleukin-6 induces cellular insulin resistance in hepatocytes","volume":"51","author":"Senn","year":"2002","journal-title":"Diabetes"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/bmm.13.13","article-title":"Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease","volume":"7","author":"Boyraz","year":"2013","journal-title":"Biomark. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2217\/bmm.13.14","article-title":"Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children","volume":"7","author":"Boyraz","year":"2013","journal-title":"Biomark. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12933-018-0707-y","article-title":"Childhood retinol-binding protein 4 (RBP4) levels predicting the 10-year risk of insulin resistance and metabolic syndrome: The BCAMS study","volume":"17","author":"Li","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Oh, K.J., Lee, D.S., Kim, W.K., Han, B.S., Lee, S.C., and Bae, K.H. (2016). Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18010008"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41419-018-0531-z","article-title":"Hepatic steatosis associated with decreased beta-oxidation and mitochondrial function contributes to cell damage in obese mice after thermal injury","volume":"9","author":"Diao","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/obr.12776","article-title":"Sarcopenia in patients with non-alcoholic fatty liver disease: Is it a clinically significant entity?","volume":"20","author":"Kwanten","year":"2019","journal-title":"Obes. Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1210\/jc.2004-0084","article-title":"Androgen receptor in human skeletal muscle and cultured muscle satellite cells: Up-regulation by androgen treatment","volume":"89","author":"Taylor","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/en.2006-1653","article-title":"Identification of androgen response elements in the insulin-like growth factor I upstream promoter","volume":"148","author":"Wu","year":"2007","journal-title":"Endocrinology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2147\/CIA.S149232","article-title":"Sarcopenia: Assessment of disease burden and strategies to improve outcomes","volume":"13","author":"Liguori","year":"2018","journal-title":"Clin. Interv. Aging"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/jgh.12695","article-title":"Testosterone in men with advanced liver disease: Abnormalities and implications","volume":"30","author":"Sinclair","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1053\/gast.1997.v113.pm9352864","article-title":"Growth hormone therapy in patients with cirrhosis: A pilot study of efficacy and safety","volume":"113","author":"Donaghy","year":"1997","journal-title":"Gastroenterology"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Bian, A., Ma, Y., Zhou, X., Guo, Y., Wang, W., Zhang, Y., and Wang, X. (2020). Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet. Disord., 21.","DOI":"10.1186\/s12891-020-03236-y"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/gerona\/glt187","article-title":"Growth hormone replacement therapy prevents sarcopenia by a dual mechanism: Improvement of protein balance and of antioxidant defenses","volume":"69","author":"Brioche","year":"2014","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1210\/jcem.87.6.8548","article-title":"GH treatment in adults with chronic liver disease: A randomized, double-blind, placebo-controlled, cross-over study","volume":"87","author":"Wallace","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: Molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"23942","DOI":"10.1073\/pnas.2014716117","article-title":"Targeting myostatin\/activin A protects against skeletal muscle and bone loss during spaceflight","volume":"117","author":"Lee","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: A proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_109","first-page":"62","article-title":"A Phase 2 Randomized Study Investigating the Efficacy and Safety of Myostatin Antibody LY2495655 versus Placebo in Patients Undergoing Elective Total Hip Arthroplasty","volume":"5","author":"Woodhouse","year":"2016","journal-title":"J. Frailty Aging"},{"key":"ref_110","first-page":"1","article-title":"Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy","volume":"2","author":"Saitoh","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle Clin. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1038\/s41598-019-47818-w","article-title":"Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease","volume":"9","author":"Pearsall","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajpath.2011.04.008","article-title":"Follistatin improves skeletal muscle healing after injury and disease through an interaction with muscle regeneration, angiogenesis, and fibrosis","volume":"179","author":"Zhu","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/mus.26113","article-title":"Locally acting ACE-083 increases muscle volume in healthy volunteers","volume":"57","author":"Glasser","year":"2018","journal-title":"Muscle Nerve"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Minetti","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study","volume":"65","author":"Rooks","year":"2017","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1164\/rccm.201802-0286OC","article-title":"Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial","volume":"199","author":"Polkey","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): A randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e2020836","DOI":"10.1001\/jamanetworkopen.2020.20836","article-title":"Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial","volume":"3","author":"Rooks","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.29107","article-title":"Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis","volume":"65","author":"Kumar","year":"2017","journal-title":"Hepatology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"8182195","DOI":"10.1155\/2019\/8182195","article-title":"L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle","volume":"2019","author":"Butterworth","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clnesp.2020.11.015","article-title":"Nutraceuticals for the treatment of sarcopenia in chronic liver disease","volume":"41","author":"Hey","year":"2021","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1172\/JCI110240","article-title":"Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis","volume":"68","author":"Owen","year":"1981","journal-title":"J. Clin. Investig."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep.1840070505","article-title":"The association of hepatic glycogen depletion with hyperammonemia in cirrhosis","volume":"7","author":"Kabadi","year":"1987","journal-title":"Hepatology"},{"key":"ref_126","first-page":"718","article-title":"The relationship of plasma polyunsaturated fatty acid deficiency with survival in advanced liver cirrhosis: Multivariate analysis","volume":"88","author":"Cabre","year":"1993","journal-title":"Am. J. Gastroenterol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41419-018-1243-0","article-title":"The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-kappaB and TGFbeta pathways in hepatic stellate cells","volume":"10","author":"Enguita","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/j.clnu.2020.09.001","article-title":"ESPEN practical guideline: Clinical nutrition in liver disease","volume":"39","author":"Bischoff","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1440-1746.2011.06951.x","article-title":"Late evening snack: Exploiting a period of anabolic opportunity in cirrhosis","volume":"27","author":"Tsien","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: A randomized 12-month trial","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clnu.2007.08.011","article-title":"Three month intervention with protein and energy rich supplements improve muscle function and quality of life in malnourished patients with non-neoplastic gastrointestinal disease\u2014A randomized controlled trial","volume":"27","author":"Norman","year":"2008","journal-title":"Clin. Nutr."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.clnu.2005.02.010","article-title":"Effects of an appropriate oral diet on the nutritional status of patients with HCV-related liver cirrhosis: A prospective study","volume":"24","author":"Manguso","year":"2005","journal-title":"Clin. Nutr."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/ajg.2011.9","article-title":"Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: A randomized study","volume":"106","author":"Les","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0016-5085(03)00323-8","article-title":"Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: A double-blind, randomized trial","volume":"124","author":"Marchesini","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1542-3565(05)00017-0","article-title":"Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis","volume":"3","author":"Muto","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0168-8278(05)80210-7","article-title":"Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebo-controlled crossover study","volume":"17","author":"Plauth","year":"1993","journal-title":"J. Hepatol."},{"key":"ref_137","first-page":"38","article-title":"Sarcopenia: Current treatments and new regenerative therapeutic approaches","volume":"23","author":"Lo","year":"2020","journal-title":"J. Orthop. Transl."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"152519","DOI":"10.1016\/j.prp.2019.152519","article-title":"The protective effect of bone marrow mesenchymal stem cells in a rat model of ischemic stroke via reducing the C-Jun N-terminal kinase expression","volume":"215","author":"Vahidinia","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12974-019-1571-8","article-title":"Neuroinflammation as a target for treatment of stroke using mesenchymal stem cells and extracellular vesicles","volume":"16","author":"Dabrowska","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.4103\/1673-5374.255978","article-title":"Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer\u2019s disease","volume":"14","year":"2019","journal-title":"Neural Regen. Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1177\/0271678X18776802","article-title":"The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke","volume":"38","author":"Cunningham","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"59","DOI":"10.15283\/ijsc.2009.2.1.59","article-title":"Cytokine secretion profiling of human mesenchymal stem cells by antibody array","volume":"2","author":"Park","year":"2009","journal-title":"Int. J. Stem Cells"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainresbull.2020.09.018","article-title":"Mesenchymal stem cells-derived mitochondria transplantation mitigates I\/R-induced injury, abolishes I\/R-induced apoptosis, and restores motor function in acute ischemia stroke rat model","volume":"165","author":"Roushandeh","year":"2020","journal-title":"Brain Res. Bull."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/3\/250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:37:18Z","timestamp":1760161038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/3\/250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,17]]},"references-count":143,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["life11030250"],"URL":"https:\/\/doi.org\/10.3390\/life11030250","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,17]]}}}